Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study.
- DOI
- 10.1080/03007995.2022.2059975
- Published
- 2022 May
- Container
- Current medical research and opinion
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1080/03007995.2022.2059975,
title = {Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study.},
author = {Pozo-Rosich P and Detke HC and Wang S and Doležil D and Li LQ and Aurora SK and Reuter U},
year = {2022},
journal = {Current medical research and opinion},
doi = {10.1080/03007995.2022.2059975},
url = {https://doi.org/10.1080/03007995.2022.2059975}
}RIS
TY - JOUR TI - Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study. AU - Pozo-Rosich P AU - Detke HC AU - Wang S AU - Doležil D AU - Li LQ AU - Aurora SK AU - Reuter U PY - 2022 JO - Current medical research and opinion DO - 10.1080/03007995.2022.2059975 UR - https://doi.org/10.1080/03007995.2022.2059975 ER -
APA
P, P., HC, D., S, W., D, D., LQ, L., SK, A., & U, R. (2022). Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study.. Current medical research and opinion. https://doi.org/10.1080/03007995.2022.2059975
Source records
- pubmed · retrieved 2026-09-26T21:21:39.704Z